Molecular Partners reports Q3 2026 results, shifts to radiopharmaceuticals, to cut nearly half of workforce

Molecular Partners AG announced unaudited Q3 2026 results and a strategic transformation to focus exclusively on radiopharmaceutical development, cutting nearly half of its workforce. The company is streamlining resources, with full implementation expected by Q2 2027 and cost reductions effective in H2 2027.

Detected & updated continuously · Source: Nebula